[1] Zhang M, Xu D, Liu Y, et al.Screening of a new candidate coxsackievirus B1 vaccine strain based on its biological characteristics[J]. Front Microbiol, 2023, 14: 1172349.
[2] Zhang C, Zhang Y, Li Y, et al.Exosome-based delivery of VP1 protein conferred enhanced resistance of mice to CVB3-induced viral myocarditis[J]. Virology, 2023, 579: 46-53.
[3] Schrijver SD, Vanhulle E, Ingenbleek A, et al.Epidemiological and clinical insights into enterovirus circulation in Europe, 2018-2023: A multicenter retrospective surveillance study[J]. J Infect Dis, 2025, 232(1): e104-e115.
[4] Cherabuddi K, Tagliamonte MS, Lednicky JA, et al.A case cluster of aseptic meningitis associated with a newly identified recombinant echovirus 6/coxsackievirus B1 enterovirus[J]. J Infect Dis, 2025, 232(3): e486-e495.
[5] Tapparel C, Siegrist F, Petty TJ, et al.Picornavirus and enterovirus diversity with associated human diseases[J]. Infect Genet Evol, 2013, 14: 282-293.
[6] Zheng Q, Zhu R, Yin Z, et al.Structural basis for the synergistic neutralization of coxsackievirus B1 by a triple-antibody cocktail[J]. Cell Host & Microbe, 2022, 30(9): 1279-1294.
[7] Kim H, Kang B, Hwang S, et al.Molecular characteristics of human coxsackievirus B1 infection in Korea, 2008-2009[J]. J Med Virol, 2013, 85(1): 110-115.
[8] Lugo D, Krogstad P.Enteroviruses in the early 21st century: New manifestations and challenges[J]. Curr Opin Pediatr, 2016, 28(1): 107-113.
[9] Zhang L, Yan J, Ojcius DM, et al.Novel and predominant pathogen responsible for the enterovirus-associated encephalitis in eastern China[J]. PLOS One, 2013, 8(12): e85023.
[10] Ji H, Fan H, Lu P X, et al.Surveillance for severe hand, foot, and mouth disease from 2009 to 2015 in Jiangsu Province: Epidemiology, etiology, and disease burden[J]. BMC Infect Dis, 2019, 19(1): 79.
[11] Guo W, Xu D, Cong S, et al.Co-infection and enterovirus B: Post EV-A71 mass vaccination scenario in China[J]. BMC Infect Dis, 2022, 22(1): 671.
[12] World Health Organization.Polio laboratory manual[M]. 4th ed. Geneva: World Health Organization, 2004.
[13] Xu DH, Zhang M, Chen JW, et al.Molecular characterization of coxsackievirus B1 strains isolated from patients with hand foot and mouth disease in Yunnan, Southwest China[J]. Biomed Environ Sci, 2024, 37(5): 543-548.
[14] 谭昭麟, 吕莉琨, 李力, 等. 天津市致病毒性脑炎柯萨奇病毒B组5型全基因组序列分析[J]. 病毒学报, 2021, 37(1): 97-105.
[15] 许丹菡, 郭伟, 张名, 等. 一株柯萨奇病毒B组5型分离株V1641/YN/CHN/2016的全基因序列分析[J]. 病毒学报, 2022, 38(3): 573-580.
[16] Liu Y, Chen J, Zhang M, et al.Coxsackievirus B: The important agent of hand, foot, and mouth disease[J]. Med Virol, 2023, 95(3): e28669.
[17] 陈俊薇, 冯昌增, 楚昭阳, 等. 一株柯萨奇病毒A组4型云南株的全基因组分析[J]. 中国感染控制杂志, 2024, 23(9): 1061-1069.
[18] Abbasi S, Makvandi M, Teimoori A, et al.Complete genome sequence of a multi-recombinant echovirus 6 strain isolated from CSF in Ahvaz, Southwestern Iran[J]. J Chin Med Assoc, 2018, 81(4): 340-347.
[19] Zhang J, Liu H, Zhao Y, et al.Identification of a new recombinant strain of echovirus 33 from children with hand, foot, and mouth disease complicated by meningitis in Yunnan, China[J]. Virol J, 2019, 16(1): 63. |
